Ligand Pharmaceuticals has received a $550,000 milestone payment following Merck’s EMA approval of NOXAFIL (posaconazole) 300 mg Concentrate Solution for Infusion. Ligand will sell Captisol to Merck for the product marketed in Europe under an existing commercial Supply Agreement . Captisol is a patented, chemically modified cyclodextrin with a structure designed to optimize the solubility and Stability of drugs.

NOXAFIL is a triazole Antifungal agent with activity against both yeast and molds responsible for serious invasive fungal infections. Merck also markets oral Suspension and Tablet formulations of NOXAFIL.